Please Click Here to share your feedback for the webinar Ascites is the most common complication of compensated liver cirrhosis, developing in about 60% of the patients within 10 years of the disease. Refractory ascites is defined as ascites that does not resolve with the standard medical treatment of low sodium diet and diuretics. It results in frequent hospital admissions with an unfavorable prognosis due to the high mortality rates. Large-volume paracentesis combined with IV albumin is considered as the first-line of treatment for refractory ascites. However, the long-term clinical benefits of this treatment are debated, with insufficient data available regarding refractory ascites.
To shed more light on the topic, Takeda and Docplexus have organized an interactive LIVE webinar on 19 th January 2022, from 7:00 PM onwards. Please join our experts; Dr. Mithun Sharma and Dr. Naveen…
